Stocks and Investing
Stocks and Investing
Tue, July 25, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Reiterated (ADCT) at Strong Buy and Held Target at $12 on, Jul 25th, 2023
Robert Burns of HC Wainwright & Co., Reiterated "ADC Therapeutics SA" (ADCT) at Strong Buy and Held Target at $12 on, Jul 25th, 2023.
Robert has made no other calls on ADCT in the last 4 months.
There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 1 agrees with Robert's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Reiterated at Hold and Held Target at $5 on, Tuesday, July 11th, 2023
These are the ratings of the 2 analyists that currently disagree with Robert
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $10 on, Wednesday, May 10th, 2023
- Tazeen Ahmad of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $2 on, Monday, April 24th, 2023
Contributing Sources